MDGL · XBRL financial data

Madrigal Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (MDGL's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue	0	0	—	—	year only	137	—	—	—	—	—	—
Revenue from contracts with customers	0*	0	15	62	103*	137	213	287	321*	311	364	431
Cost of goods and services sold	year only	0	—	—	year only	5	—	—	—	—	—	—
Selling, general and administrative	47*	81	105	108	141*	168	197	209	240*	269	289	266
General and administrative	47	—	—	—	—	—	—	—	—	—	—	—
Total operating expenses	117	152	177	178	170*	217	260	401	381*	404	421	375
Operating income (loss)	(117)	(152)	(163)	(116)	(67)*	(79)	(47)	(114)	(60)*	(93)	(56)	56
Interest income	9	8	14	13	11*	9	8	10	9*	8	7	8
Interest expense	4	4	4	4	3*	3	3	7	8*	8	8	8
Other income (expense)	year only	—	0	0	0*	0	(0)	(0)	(0)*	(2)	(1)	(1)
Income tax expense (benefit)	year only	—	—	—	year only	—	—	—	year only	—	—	—
Net income (loss)	(112)	(148)	(152)	(107)	(59)*	(73)	(42)	(114)	(59)*	(94)	(58)	55
Earnings per share, basic USD per share	(5.68)	(7.38)	(7.10)	(4.92)	(2.71)*	(3.32)	(1.90)	(5.08)	(2.55)*	(3.25)	(1.99)	1.90
Earnings per share, diluted USD per share	(5.68)	(7.38)	(7.10)	(4.92)	(2.71)*	(3.32)	(1.90)	(5.08)	(2.55)*	(3.25)	(1.99)	1.83
Weighted average shares, basic millions of shares	20	20	21	22	22*	22	22	22	23*	29	29	29
Weighted average shares, diluted millions of shares	20	20	21	22	22*	22	22	22	23*	29	29	30

Fiscal quarters (MDGL's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	100	623	495	233	100	184	186	296	199	227	293	515
Marketable securities	534	437	563	766	826	659	611	814	785	586	546	446
Accounts receivable	0	—	7	30	54	61	79	113	134	187	192	227
Inventory	0	1	7	9	34	55	63	69	75	112	99	123
Prepaid and other current assets	3	14	15	21	14	23	59	49	48	65	69	75
Total current assets	637	1,074	1,092	1,064	1,033	988	1,003	1,347	1,246	1,182	1,199	1,387
Property and equipment, net	2	2	2	2	2	2	2	3	1	8	12	14
Right-of-use asset	2	2	1	3	2	2	6	5	5	6	6	13
Total assets	641	1,082	1,100	1,073	1,042	997	1,015	1,362	1,260	1,227	1,245	1,434
Accounts payable	28	22	9	46	44	42	38	45	49	61	35	61
Accrued liabilities	90	92	116	131	125	124	157	345	260	276	339	392
Total current liabilities	119	114	125	178	169	167	197	391	310	338	374	454
Long-term debt	115	116	117	117	118	118	118	340	340	340	341	341
Lease liability, non-current	1	1	1	1	1	1	5	6	7	5	6	12
Total liabilities	235	232	243	296	288	286	319	737	657	684	721	807
Accumulated deficit	(1,336)	(1,484)	(1,636)	(1,743)	(1,802)	(1,875)	(1,918)	(2,032)	(2,090)	(2,185)	(2,243)	(2,187)
Total stockholders' equity	405	851	857	777	754	711	696	626	603	543	524	627
Total liabilities and equity	641	1,082	1,100	1,073	1,042	997	1,015	1,362	1,260	1,227	1,245	1,434
Common shares outstanding (cover page) millions of shares	20	21	22	22	22	22	22	23	23	23	23	23

Fiscal quarters (MDGL's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(112)	(148)	(152)	(107)	(59)*	(73)	(42)	(114)	(59)*	(94)	(58)	55
Stock-based compensation	15*	20	24*	18*	18*	21	25*	26*	26*	34	35*	39*
Depreciation and amortization	0*	0	0*	0*	0*	0	0*	0*	0*	0	0*	0*
Net cash from operating activities	(80)*	(149)	(135)*	(67)*	(104)*	(89)	(47)*	80*	(133)*	(167)	23*	121*
Purchases of property and equipment	1*	0	0*	1*	0*	0	0*	1*	(0)*	4	4*	4*
Net cash from investing activities	(362)*	98	(122)*	(202)*	(48)*	164	48*	(207)*	28*	192	34*	94*
Net cash from financing activities	480*	574	134*	7*	20*	9	2*	237*	9*	2	3*	10*
Net change in cash	38*	523	(123)*	(262)*	(133)*	84	3*	110*	(97)*	28	61*	223*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Madrigal Pharmaceuticals	515	431	not reported	23.2M	—	Q3 FY26 10-QSep 30, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026
Repligen	727	209	43*	63.9M	—	Q3 FY26 10-QSep 30, 2026
Corcept Therapeutics	111	256	34*	108.1M	—	Q2 FY26 10-QJun 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Biomarin Pharmaceutical	874	990	168*	193.6M	—	Q2 FY26 10-QJun 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Alkermes	631	480	93*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.